Does progress achieved in the treatment of patients with metastatic non-small-cell lung cancer reach the elderly population? A cohort study from a cancer centre from Eastern Switzerland.
Adenocarcinoma of Lung
/ drug therapy
Age Factors
Aged
Antineoplastic Agents, Immunological
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cancer Care Facilities
Carcinoma, Large Cell
/ drug therapy
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Cohort Studies
Female
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Metastasis
Platinum Compounds
/ administration & dosage
Protein Kinase Inhibitors
/ therapeutic use
Survival Rate
/ trends
Switzerland
advanced NSCLC
elderly
immunotherapy
targeted treatment
treatment advances
undertreatment
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
28
03
2019
revised:
11
11
2019
accepted:
22
11
2019
pubmed:
23
1
2020
medline:
5
1
2021
entrez:
23
1
2020
Statut:
ppublish
Résumé
Treatment options for non-small-cell lung cancer (NSCLC) have been evolving. The goal of our study was to evaluate whether novel therapeutics are used in the elderly population and improve outcomes to a similar extent as in young patients. We enrolled patients registered in the Cancer Registry of Eastern Switzerland and grouped them into four cohorts: Elderly patients aged ≥70 years diagnosed 2005-2007 and 2015-2016 (elderly cohorts 1,2) were compared to cohorts of patients < 70 years diagnosed during the same time periods (young cohorts 1,2). 499 individuals were analysed. Median cancer-specific survival in the elderly cohorts 1 and 2 was 3.9 months and 6.3 months, respectively, and 8.0 and 12.7 months in the young cohorts 1 and 2. 12-month survival significantly improved over ten years only in younger patients (35.6% and 54.9%), however not in the elderly cohorts (20% vs. 35%). Proportion of patients receiving any line of systemic treatment remained lower in the elderly cohorts (53% vs. 78%). Despite the increase in median cancer-specific survival in both cohorts, a significant and clinically meaningful improvement of 12-month cancer-specific survival was only seen in young patients. The adoption of novel treatment approaches is lagging behind in the elderly population.
Substances chimiques
Antineoplastic Agents, Immunological
0
Platinum Compounds
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Pagination
e13206Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., … Brahmer, J.R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(17), 1627-1639. https://doi.org/10.1056/NEJMoa1507643
Bosetti, C., Bertuccio, P., Malvezzi, M., Levi, F., Chatenoud, L., Negri, E., & La Vecchia, C. (2013). Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Annals of Oncology, 24(10), 2657-2671. https://doi.org/10.1093/annonc/mdt301
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., … Spigel, D.R. (2015). Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(2), 123-135. https://doi.org/10.1056/NEJMoa1504627
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
Casaluce, F., Sgambato, A., Maione, P., Spagnuolo, A., & Gridelli, C. (2018). Lung cancer, elderly and immune checkpoint inhibitors. Journal of Thoracic Disease, 10(Suppl 13), S1474-S1481. https://doi.org/10.21037/jtd.2018.05.90
Davidoff, A.J., Gardner, J.F., Seal, B., & Edelman, M.J. (2011). Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. Journal of Thoracic Oncology, 6(5), 934-941. https://doi.org/10.1097/JTO.0b013e31820eed00
Davidoff, A.J., Tang, M., Seal, B., & Edelman, M.J. (2010). Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(13), 2191-2197. https://doi.org/10.1200/JCO.2009.25.4052
Des Guetz, G., Uzzan, B., Nicolas, P., Valeyre, D., Sebbane, G., & Morere, J.F. (2012). Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis. Critical Reviews in Oncology Hematology, 84(3), 340-349. https://doi.org/10.1016/j.critrevonc.2012.03.007
Ess, S.M., Herrmann, C., Frick, H., Krapf, M., Cerny, T., Jochum, W., & Fruh, M. (2017). Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. European Journal of Cancer Care, 26(6), e12721-https://doi.org/10.1111/ecc.12721
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., …Group, P. S (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0
Gridelli, C., Brodowicz, T., Langer, C.J., Peterson, P., Islam, M., Guba, S.C., … Scagliotti, G. (2012). Pemetrexed therapy in elderly patients with good performance status: Analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clinical Lung Cancer, 13(5), 340-346. https://doi.org/10.1016/j.cllc.2011.12.002
Gridelli, C., Morabito, A., Cavanna, L., Luciani, A., Maione, P., Bonanno, L., … Perrone, F. (2018). Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials. Journal of Clinical Oncology, 36(25), 2585-2592. https://doi.org/10.1200/JCO.2017.76.8390
Gridelli, C., Perrone, F., Gallo, C., Cigolari, S., Rossi, A., Piantedosi, F., … Gebbia, V. (2003). Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. Journal of the National Cancer Institute, 95(5), 362-372. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12618501. https://doi.org/10.1093/jnci/95.5.362
Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., … Garon, E.B. (2015). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 387(10027), 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., … Wherry, E.J. (2017). T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature, 545(7652), 60-65. https://doi.org/10.1038/nature22079
Inoue, A., Kobayashi, K., Usui, K., Maemondo, M., Okinaga, S., & Mikami, I., …North East Japan Gefitinib Study, G (2009). First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. Journal of Clinical Oncology, 27(9), 1394-1400. https://doi.org/10.1200/JCO.2008.18.7658
Jennens, R.R., Giles, G.G., & Fox, R.M. (2006). Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Internal Medicine Journal, 36(4), 216-220. https://doi.org/10.1111/j.1445-5994.2006.01033.x
Krebsliga. (2019). https://www.krebsliga.ch/ueber-krebs/zahlen-fakten/-dl-/fileadmin/downloads/sheets/zahlen-krebs-in-der-schweiz.pdf [Accessed 19 Feb. 2019].
Kudoh, S., Takeda, K., Nakagawa, K., Takada, M., Katakami, N., Matsui, K., … Fukuoka, M. (2006). Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). Journal of Clinical Oncology, 24(22), 3657-3663. https://doi.org/10.1200/JCO.2006.06.1044
Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., … Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947-957. https://doi.org/10.1056/NEJMoa0810699
Mousavi, S.M., Schmid, S., Cerny, T., & Fruh, M. (2018). Lung cancer and smoking trends in the young in Switzerland: A study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys. Swiss Medical Weekly, 148, w14708. https://doi.org/10.4414/smw.2018.14708
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., … Peters, S. (2018). Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29(Supplement_4), iv192-iv237. https://doi.org/10.1093/annonc/mdy275
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., … Peters, S. (2019). Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 30(5), 863-870. https://doi.org/10.1093/annonc/mdy474
Popat, S., Ardizzoni, A., Ciuleanu, T., Cobo Dols, M., Laktionov, K., Szilasi, M., Felip, E. (2017). Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. ESMO 2017.
Qi, W.X., Tang, L.N., He, A.N., Shen, Z., Lin, F., & Yao, Y. (2012). Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis. Lung, 190(5), 477-485. https://doi.org/10.1007/s00408-012-9399-3
Quoix, E., Zalcman, G., Oster, J.-P., Westeel, V., Pichon, E., Lavolé, A., … Milleron, B. (2011). Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet, 378(9796), 1079-1088. https://doi.org/10.1016/S0140-6736(11)60780-0
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., … Brahmer, J.R. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine, 375(19), 1823-1833. https://doi.org/10.1056/NEJMoa1606774
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., … Paz-Ares, L. (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. The Lancet Oncology, 13(3), 239-246. https://doi.org/10.1016/S1470-2045(11)70393-X
Sequist, L.V., Yang, J.C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., … Schuler, M. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), 3327-3334. https://doi.org/10.1200/JCO.2012.44.2806
Sgambato, A., Casaluce, F., & Gridelli, C. (2017). The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. Expert Opin Biol Ther, 17(5), 565-571. https://doi.org/10.1080/14712598.2017.1294157
Shaw, A.T., Kim, D.W., Nakagawa, K., Seto, T., Crino, L., Ahn, M.J., … Janne, P.A. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. New England Journal of Medicine, 368(25), 2385-2394. https://doi.org/10.1056/NEJMoa1214886
Solomon, B.J., Mok, T., Kim, D.W., Wu, Y.L., Nakagawa, K., Mekhail, T., … Investigators, P. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine, 371(23), 2167-2177. https://doi.org/10.1056/NEJMoa1408440
The Elderly Lung Cancer Vinorelbine Italian Study Group. (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Journal of the National Cancer Institute, 91(1), 66-72. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9890172.
Yee, K.W., Pater, J.L., Pho, L., Zee, B., & Siu, L.L. (2003). Enrollment of older patients in cancer treatment trials in Canada: Why is age a barrier? Journal of Clinical Oncology, 21(8), 1618-1623. https://doi.org/10.1200/JCO.2003.12.044